In June 2021, after discovering a potential health risk related to a part in specific CPAP, BiPAP and Mechanical Ventilator devices, Philips issued a voluntary Field Safety Notice (FSN 2021-05-A & FSN 2021-06-A).
We continue to work with independent partners to conduct extensive testing and analysis of results on affected devices, including biocompatibility evaluations.
Please check this page for updates frequently as we will add new testing results documents as they become available.
Summary of a systematic literature review of Positive Airway Pressure device use and cancer risk
July 25, 2022
Philips Respironics engaged external scientific experts to perform an independent systematic literature review of epidemiological studies to evaluate whether use of Continuous or Bilevel Positive Airway Pressure (PAP) devices increases the risk of cancer in obstructive sleep apnea (OSA) patients.
Based on 13 epidemiological studies identified from the systematic literature review, no association has been established between use of PAP devices, including Philips Respironics PAP devices, and risk of cancer in patients with OSA. Two rigorous independent studies showed no statistical difference in cancer risk between OSA patients who used Philips Respironics PAP devices versus other brands of PAP devices. Eleven other epidemiological studies provided little additional insight into this question, but their results generally suggested no excess risk of cancer associated with PAP use for OSA.
0800 249 4578 (UK) or (0044) 20 8089 3822 (outside of UK)
By clicking on the link, you will be leaving the official Royal Philips ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.